About me
Dr. Jacobs holds a BS degree from Davidson College and a Ph.D. in molecular biology from Washington University in St. Louis. With over 25 years of experience in the healthcare industry, he has specialized in supervising drug manufacturing operations, designing preclinical animal trials, and leading US FDA-authorized clinical trials. Dr. Jacobs played a key role in establishing the Department of Biological Chemistry at Merck and served as the Chief Science Officer for CardioVascular BioTherapeutics, Inc. for 15 years. There, he oversaw groundbreaking FDA-approved clinical trials involving the angiogenesis drug candidate human FGF-1, testing its effectiveness in treating coronary artery disease, diabetic foot ulcers, and peripheral artery disease. Currently, Dr. Jacobs continues his work at Zhittya Genesis Medicine, focusing on the potential of therapeutic angiogenesis to treat neurodegenerative diseases, such as Parkinson’s disease.
